Global

Andaman7 and Afrisda, Inc. sign partnership agreement to support digital health implementation in Africa.

Pandemic triggers urgency around supply chain initiatives.

The European Commission’s Genetically Modified Organism (GMO) legislation hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, say European industry associations.

Becton, Dickinson and Company is to build a $200 million high-tech manufacturing facility in Zaragoza, Spain.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.

The progress and stumbling blocks in building a formal EU system.

The drive for “vaccine equity” around the world is bolstering efforts to limit patent protections on innovative medicines and vaccines to combat the global pandemic.

Rosanne Rotondo talks to Pharm Exec about recent breakthroughs in the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis and the work of Novartis’ other Global Health Flagship Programs.

Draft plan looks beyond the immediate European health challenges.

Latest proposal explores boosting the powers of the EMA.

Rajit Kamal, Vice President, Asia Pacific for DePuy Synthes, a Johnson & Johnson company, offers recommendations for those wishing to secure an expatriate assignment with their company.

The European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.

Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

Can private sector serve public interests in battling rare diseases?

How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Sam Pearce, SVP, Head of Europe and International at Jazz Pharmaceuticals, talks about joining the company during a transformative period and how she is working to foster a bold and collaborative culture to expand Jazz’s footprint in Europe and beyond.

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

On December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.

EU tasked with translating bold declarations into reality.

Must find common ground between digitalization and protection laws.

Must maintain trust in face of customary, non-pandemic challenges.

Universal strategy push elicits range of constituency views.

Orphan drug incentives set to remain in place in Europe.